Levosimendan: Beyond its simple inotropic effect in heart failure

Pharmacology and Therapeutics

Volumn 114, Issue 2, 2007, Pages 184-197

  Antoniades, Charalambos ^a   Tousoulis, Dimitris ^a   Koumallos, Nikolaos ^a   Marinou, Kyriakoula ^a   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Ca2+ sensitizers; Heart failure; Levosimendan; Myocardial function

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; CALCIUM ACTIVATED POTASSIUM CHANNEL; CALCIUM ANTAGONIST; CALCIUM ION; CALCIUM SENSITIZER; DOBUTAMINE; DRUG METABOLITE; INOTROPIC AGENT; LEVOSIMENDAN; N [4 (1,4,5,6 TETRAHYDRO 4 METHYL 6 OXO 3 PYRIDAZINYL)PHENYL]ACETAMIDE; PHOSPHODIESTERASE INHIBITOR; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ATRIOVENTRICULAR CONDUCTION; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG HALF LIFE; HEADACHE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART HEMODYNAMICS; HEART MUSCLE ISCHEMIA; HEART PROARRHYTHMIA; HEART PROTECTION; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPOTENSION; INOTROPISM; MEAN ARTERIAL PRESSURE; MORTALITY; NAUSEA; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; QT PROLONGATION; REVIEW; SIDE EFFECT; SINUS NODE; SINUS RHYTHM; STUNNED HEART MUSCLE; SYMPTOMATOLOGY; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; VASODILATATION;

CALCIUM; CARDIAC OUTPUT; CARDIOTONIC AGENTS; DRUG INTERACTIONS; HEART FAILURE, CONGESTIVE; HUMANS; HYDRAZONES; POTASSIUM CHANNELS; PYRIDAZINES; VASODILATION; VASODILATOR AGENTS;

EID: 34147165047     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2007.01.008     Document Type: Review

References (109)

1. Adamopoulos S., Parissis J.T., and Kremastinos D.T. A glossary of circulating cytokines in chronic heart failure. Eur J Heart Fail 3 5 (2001) 517-526
2. Ajiro Y., Hagiwara N., Katsube Y., Sperelakis N., and Kasanuki H. Levosimendan increases L-type Ca(2+) current via phosphodiesterase-3 inhibition in human cardiac myocytes. Eur J Pharmacol 435 1 (2002) 27-33
3. Anker S.D., Egerer K.R., Volk H.D., Kox W.J., Poole-Wilson P.A., and Coats A.J. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol 79 10 (1997) 1426-1430
4. Antila S., Eha J., Heinpalu M., Lehtonen L., Loogna I., Mesikepp A., et al. Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril. Eur J Clin Pharmacol 49 6 (1996) 451-458
5. Antila S., Huuskonen H., Nevalainen T., Kanerva H., Vanninen P., and Lehtonen L. Site dependent bioavailability and metabolism of levosimendan in dogs. Eur J Pharm Sci 9 1 (1999) 85-91
6. Antila S., Kivikko M., Lehtonen L., Eha J., Heikkila A., Pohjanjousi P., et al. Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan. Br J Clin Pharmacol 57 4 (2004) 412-415
7. Boknik P., Neumann J., Kaspareit G., Schmitz W., Scholz H., Vahlensieck U., et al. Mechanisms of the contractile effects of levosimendan in the mammalian heart. J Pharmacol Exp Ther 280 1 (1997) 277-283
8. Bolli R., and Marban E. Molecular and cellular mechanisms of myocardial stunning. Physiol Rev 79 2 (1999) 609-634
9. Bowman P., Haikala H., and Paul R.J. Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization. J Pharmacol Exp Ther 288 1 (1999) 316-325
10. Brixius K., Reicke S., and Schwinger R.H. Beneficial effects of the Ca(2+) sensitizer levosimendan in human myocardium. Am J Physiol Heart Circ Physiol 282 1 (2002) H131-H137
11. Ceconi C., Curello S., Bachetti T., Corti A., and Ferrari R. Tumor necrosis factor in congestive heart failure: a mechanism of disease for the new millennium?. Prog Cardiovasc Dis 41 1 Suppl 1 (1998) 25-30
12. 2+] to left ventricular relationships before and after ischemia in isolated guinea pig hearts. Cardiovasc Res 59 4 (2003) 912-925
13. Cleland J.G., Ghosh J., Freemantle N., Kaye G.C., Nasir M., Clark A.L., et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail 6 4 (2004) 501-508
14. Cleland J.G., Freemantle N., Coletta A.P., and Clark A.L. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail 8 1 (2006) 105-110
15. De Luca L., Colucci W.S., Nieminen M.S., Massie B.M., and Gheorghiade M. Evidence-based use of levosimendan in different clinical settings. Eur Heart J 27 16 (2006) 1908-1920
16. De Luca L., Proietti P., Cellotto A., Bucciavelli-Ducci C., Benedetti G., Di Roma A., et al. Levosimendan improves hemodynamic and coronary flow reserve after percutaneous coronary intervention in patients with acute myocardial infarction and left ventricular dysfunction. Am Heart J 150 2 (2005) 563-568
17. De Luca L., Sardella G., Proietti P., Battagliese A., Benedetti G., Di Roma A., et al. Effects of levosimendan on left ventricular diastolic function after primary angioplasty for acute anterior myocardial infarction: a Doppler echocardiographic study. J Am Soc Echocardiogr 19 2 (2006) 172-177
18. De Witt B.J., Ibrahim I.N., Bayer E., Fields A.M., Richards T.A., Banister R.E., et al. An analysis of responses to levosimendan in the pulmonary vascular bed of the cat. Anesth Analg 94 6 (2002) 1427-1433 (table of contents)
19. Du Toit E.F., Muller C.A., McCarthy J., and Opie L.H. Levosimendan: effects of a calcium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischemia/reperfusion in the Langendorff-perfused guinea pig heart. J Pharmacol Exp Ther 290 2 (1999) 505-514
20. du Toit E., Hofmann D., McCarthy J., and Pineda C. Effect of levosimendan on myocardial contractility, coronary and peripheral blood flow, and arrhythmias during coronary artery ligation and reperfusion in the in vivo pig model. Heart 86 1 (2001) 81-87
21. 2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res 77 1 (1995) 107-113
22. Erdei N., Papp Z., Pollesello P., Edes I., and Bagi Z. The levosimendan metabolite OR-1896 elicits vasodilation by activating the K(ATP) and BK(Ca) channels in rat isolated arterioles. Br J Pharmacol 148 5 (2006) 696-702
23. Eriksson O., Pollesello P., and Haikala H. Effect of levosimendan on balance between ATP production and consumption in isolated perfused guinea-pig heart before ischemia or after reperfusion. J Cardiovasc Pharmacol 44 3 (2004) 316-321
24. Fischbach P.S., White A., Barrett T.D., and Lucchesi B.R. Risk of ventricular proarrhythmia with selective opening of the myocardial sarcolemmal versus mitochondrial ATP-gated potassium channel. J Pharmacol Exp Ther 309 2 (2004) 554-559
25. Follath F., Cleland J.G., Just H., Papp J.G., Scholz H., Peuhkurinen K., et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 360 9328 (2002) 196-202
26. Gross G.J., and Fryer R.M. Sarcolemmal versus mitochondrial ATP-sensitive K+ channels and myocardial preconditioning. Circ Res 84 9 (1999) 973-979
27. Gross G.J., and Peart J.N. KATP channels and myocardial preconditioning: an update. Am J Physiol Heart Circ Physiol 285 3 (2003) H921-H930
28. Gruhn N., Nielsen-Kudsk J.E., Theilgaard S., Bang L., Olesen S.P., and Aldershvile J. Coronary vasorelaxant effect of levosimendan, a new inodilator with calcium-sensitizing properties. J Cardiovasc Pharmacol 31 5 (1998) 741-749
29. Haikala H., and Linden I.B. Mechanisms of action of calcium-sensitizing drugs. J Cardiovasc Pharmacol 26 Suppl 1 (1995) S10-S19
30. Haikala H., and Pollesello P. Calcium sensitivity enhancers. IDrugs 3 10 (2000) 1199-1205
31. Haikala H., Nissinen E., Etemadzadeh E., Levijoki J., and Linden I.B. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol 25 5 (1995) 794-801
32. Haikala H., Kaheinen P., Levijoki J., and Linden I.B. The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan. Cardiovasc Res 34 3 (1997) 536-546
33. Hajjar R.J., Schmidt U., Helm P., and Gwathmey J.K. Ca++ sensitizers impair cardiac relaxation in failing human myocardium. J Pharmacol Exp Ther 208 1 (1997) 247-254
34. Hanley P.J., and Daut J. K(ATP) channels and preconditioning: a re-examination of the role of mitochondrial K(ATP) channels and an overview of alternative mechanisms. J Mol Cell Cardiol 39 1 (2005) 17-50
35. Harkin C.P., Pagel P.S., Tessmer J.P., and Warltier D.C. Systemic and coronary hemodynamic actions and left ventricular functional effects of levosimendan in conscious dogs. J Cardiovasc Pharmacol 26 2 (1995) 179-188
36. Hasenfuss G., Mulieri L.A., Leavitt B.J., and Alpert N.R. Influence of isoproterenol on contractile protein function, excitation-contraction coupling, and energy turnover of isolated nonfailing human myocardium. J Mol Cell Cardiol 26 11 (1994) 1461-1469
37. Hasenfuss G., Pieske B., Kretschmann B., Holubarsch C., Alpert N.R., and Just H. Effects of calcium sensitizers on intracellular calcium handling and myocardial energetics. J Cardiovasc Pharmacol 26 Suppl 1 (1995) S45-S51
38. Hasenfuss G., Pieske B., Castell M., Kretschmann B., Maier L.S., and Just H. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation 98 20 (1998) 2141-2147
39. Hohn J., Pataricza J., Petri A., Toth G.K., Balogh A., Varro A., et al. Levosimendan interacts with potassium channel blockers in human saphenous veins. Basic Clin Pharmacol Toxicol 94 6 (2004) 271-273
40. Kaheinen P., Pollesello P., Levijoki J., and Haikala H. Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. J Cardiovasc Pharmacol 37 4 (2001) 367-374
41. Kaheinen P., Pollesello P., Levijoki J., and Haikala H. Effects of levosimendan and milrinone on oxygen consumption in isolated guinea-pig heart. J Cardiovasc Pharmacol 43 4 (2004) 555-561
42. Kersten J.R., Montgomery M.W., Pagel P.S., and Warltier D.C. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth Analg 90 1 (2000) 5-11
43. Kivikko M., Antila S., Eha J., Lehtonen L., and Pentikainen P.J. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. J Clin Pharmacol 42 1 (2002) 43-51
44. Kivikko M., Antila S., Eha J., Lehtonen L., and Pentikainen P.J. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther 40 10 (2002) 465-471
45. Kivikko M., Lehtonen L., and Colucci W.S. Sustained hemodynamic effects of intravenous levosimendan. Circulation 107 1 (2003) 81-86
46. Kopustinskiene D.M., Pollesello P., and Saris N.E. Levosimendan is a mitochondrial K(ATP) channel opener. Eur J Pharmacol 428 3 (2001) 311-314
47. Kopustinskiene D.M., Pollesello P., and Saris N.E. Potassium-specific effects of levosimendan on heart mitochondria. Biochem Pharmacol 68 5 (2004) 807-812
48. Koumallos N., Antoniades C., Tousoulis D., Shirodaria C., and Stefanadis C. Levosimendan: a novel agent in heart failure. Rec Patents Cardiovasc Drugs Disc 1 2 (2006) 185-192
49. Kristof E., Szigeti G., Papp Z., Bodi A., Facsko A., Kovacs L., et al. Cardiac responses to calcium sensitizers and isoproterenol in intact guinea pig hearts. Effects on cyclic AMP levels, protein phosphorylation, myoplasmic calcium concentration, and left ventricular function. Ann N Y Acad Sci 853 (1998) 316-319
50. Krown K.A., Page M.T., Nguyen C., Zechner D., Gutierrez V., Comstock K.L., et al. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest 98 12 (1996) 2854-2865
51. Kyrzopoulos S., Adamopoulos S., Parissis J.T., Rassias J., Kostakis G., Iliodromitis E., et al. Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients. Int J Cardiol 99 3 (2005) 409-413
52. i in guinea-pig isolated ventricular myocytes. Eur J Pharmacol 339 1 (1997) 97-100
53. Lehtonen L., and Sundberg S. The contractility enhancing effect of the calcium sensitiser levosimendan is not attenuated by carvedilol in healthy subjects. Eur J Clin Pharmacol 58 7 (2002) 449-452
54. Lilleberg J., Sundberg S., and Nieminen M.S. Dose-range study of a new calcium sensitizer, levosimendan, in patients with left ventricular dysfunction. J Cardiovasc Pharmacol 26 Suppl 1 (1995) S63-S69
55. Lilleberg J., Nieminen M.S., Akkila J., Heikkila L., Kuitunen A., Lehtonen L., et al. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J 19 4 (1998) 660-668
56. Lilleberg J., Ylonen V., Lehtonen L., and Toivonen L. The calcium sensitizer levosimendan and cardiac arrhythmias: an analysis of the safety database of heart failure treatment studies. Scand Cardiovasc J 38 2 (2004) 80-84
57. Lilleberg J., Laine M., Palkama T., Kivikko M., Pohjanjousi P., and Kupari M. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure. Eur J Heart Fail (2006)
58. Majerus T.C., Dasta J.F., Bauman J.L., Danziger L.H., and Ruffolo Jr. R.R. Dobutamine: ten years later. Pharmacotherapy 9 4 (1989) 245-259
59. Mebazaa A. The SURVIVE-W trial: comparison of dobutamine and levosimendan on survival in acute decompensated heart failure. Program and abstracts from the American Heart Association Scientific Sessions, Dallas, Texas (Late Breaking Clinical Trials IV) (2005)
60. Mebazaa A., Barraud D., and Welschbillig S. Randomized clinical trials with levosimendan. Am J Cardiol 96 6A (2005) 74G-79G
61. Michaels A.D., McKeown B., Kostal M., Vakharia K.T., Jordan M.V., Gerber I.L., et al. Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation 111 12 (2005) 1504-1509
62. Moiseyev V.S., Poder P., Andrejevs N., Ruda M.Y., Golikov A.P., Lazebnik L.B., et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 23 18 (2002) 1422-1432
63. Nanas J.N., Papazoglou P.P., Terrovitis J.V., Kanakakis J., Dalianis A., Tsolakis E., et al. Hemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine alone. Am J Cardiol 94 10 (2004) 1329-1332
64. Nieminen M.S., Akkila J., Hasenfuss G., Kleber F.X., Lehtonen L.A., Mitrovic V., et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 36 6 (2000) 1903-1912
65. Nijhawan N., Nicolosi A.C., Montgomery M.W., Aggarwal A., Pagel P.S., and Warltier D.C. Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial. J Cardiovasc Pharmacol 34 2 (1999) 219-228
66. Nony P., Boissel J.P., Lievre M., Leizorovicz A., Haugh M.C., Fareh S., et al. Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients: a meta-analysis. Eur J Clin Pharmacol 46 3 (1994) 191-196
67. Oldenburg O., Cohen M.V., Yellon D.M., and Downey J.M. Mitochondrial K(ATP) channels: role in cardioprotection. Cardiovasc Res 55 3 (2002) 429-437
68. Packer M. REVIVE II: multicenter placebo-controlled trial of levosimendan on clinical status in acutely decompensated heart failure. Program and abstracts from the American Heart Association Scientific Sessions, Dallas, Texas (Late Breaking Clinical Trials II) (2005)
69. Packer M., Carver J.R., Rodeheffer R.J., Ivanhoe R.J., DiBianco R., Zeldis S.M., et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 325 21 (1991) 1468-1475
70. Pagel P.S., Harkin C.P., Hettrick D.A., and Warltier D.C. Levosimendan (OR-1259), a myofilament calcium sensitizer, enhances myocardial contractility but does not alter isovolumic relaxation in conscious and anesthetized dogs. Anesthesiology 81 4 (1994) 974-987
71. Pagel P.S., Hettrick D.A., and Warltier D.C. Comparison of the effects of levosimendan, pimobendan, and milrinone on canine left ventricular-arterial coupling and mechanical efficiency. Basic Res Cardiol 91 4 (1996) 296-307
72. Pagel P.S., McGough M.F., Hettrick D.A., Lowe D., Tessmer J.P., Jamali I.N., et al. Levosimendan enhances left ventricular systolic and diastolic function in conscious dogs with pacing-induced cardiomyopathy. J Cardiovasc Pharmacol 29 5 (1997) 563-573
73. Papp J.G., Pollesello P., Varro A.F., and Vegh A.S. Effect of levosimendan and milrinone on regional myocardial ischemia/reperfusion-induced arrhythmias in dogs. J Cardiovasc Pharmacol Ther 11 2 (2006) 129-135
74. Paraskevaidis I.A., Parissis J.T., and Th Kremastinos D. Anti-inflammatory and anti-apoptotic effects of levosimendan in decompensated heart failure: a novel mechanism of drug-induced improvement in contractile performance of the failing heart. Curr Med Chem Cardiovasc Hematol Agents 3 3 (2005) 243-247
75. Parissis J.T., Adamopoulos S., Antoniades C., Kostakis G., Rigas A., Kyrzopoulos S., et al. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 93 10 (2004) 1309
76. Parissis J.T., Panou F., Farmakis D., Adamopoulos S., Filippatos G., Paraskevaidis I., et al. Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am J Cardiol 96 3 (2005) 423-426
77. Parissis J.T., Farmakis D., and Kremastinos D.T. Levosimendan therapy in decompensated chronic heart failure: favourable haemodynamic and neurohormonal effects but for how long?. Eur J Heart Fail 8 2 (2006) 215
78. Pataricza J., Hohn J., Petri A., Balogh A., and Papp J.G. Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein. J Pharm Pharmacol 52 2 (2000) 213-217
79. Pataricza J., Krassoi I., Hohn J., Kun A., and Papp J.G. Functional role of potassium channels in the vasodilating mechanism of levosimendan in porcine isolated coronary artery. Cardiovasc Drugs Ther 17 2 (2003) 115-121
80. Peart J.N., and Gross G.J. Sarcolemmal and mitochondrial K(ATP) channels and myocardial ischemic preconditioning. J Cell Mol Med 6 4 (2002) 453-464
81. Poder P., Eha J., Antila S., Heinpalu M., Planken U., Loogna I., et al. Pharmacodynamic interactions of levosimendan and felodipine in patients with coronary heart disease. Cardiovasc Drugs Ther 17 5-6 (2003) 451-458
82. 2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study. J Biol Chem 269 46 (1994) 28584-28590
83. Raasmaja A., Talo A., Nissinen E., Linden I.B., and Pohto P. Biochemical mechanisms of the novel cardiotonic agent OR-1259. J Mol Cell Cardiol 23 Suppl V (1991) S129
84. Rump A.F., Acar D., Rosen R., and Klaus W. Functional and antiischaemic effects of the phosphodiesterase inhibitor levosimendan in isolated rabbit hearts. Pharmacol Toxicol 74 4-5 (1994) 244-248
85. Sandell E.P., Hayha M., Antila S., Heikkinen P., Ottoila P., Lehtonen L.A., et al. Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure. J Cardiovasc Pharmacol 26 Suppl 1 (1995) S57-S62
86. 2+ transients in aequorin-loaded right-ventricular papillary muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit. J Mol Cell Cardiol 30 6 (1998) 1115-1128
87. Shahid M., and Nicholson C.D. Comparison of cyclic nucleotide phosphodiesterase isoenzymes in rat and rabbit ventricular myocardium: positive inotropic and phosphodiesterase inhibitory effects of Org 30029, milrinone and rolipram. Naunyn Schmiedebergs Arch Pharmacol 342 6 (1990) 698-705
88. Singh B.N., Lilleberg J., Sandell E.-P., Ylonen V., Lehtonen L., and Toivonen L. Effects of levosimendan on cardiac arrhythmia: electrophysiologic and ambulatory electrocardiographic findings in phase II and phase III clinical studies in cardiac failure. Am J Cardiol 83 12, Supplement 2 (1999) 16
89. Slawsky M.T., Colucci W.S., Gottlieb S.S., Greenberg B.H., Haeusslein E., Hare J., et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation 102 18 (2000) 2222-2227
90. 2+ sensitization predominantly enhances function and mechanical efficiency of stunned myocardium. Circulation 90 2 (1994) 959-969
91. Sonntag S., Sundberg S., Lehtonen L.A., and Kleber F.X. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J Am Coll Cardiol 43 12 (2004) 2177-2182
92. Sundberg S., and Lehtonen L. Haemodynamic interactions between the novel calcium sensitiser levosimendan and isosorbide-5-mononitrate in healthy subjects. Eur J Clin Pharmacol 55 11-12 (2000) 793-799
93. Sundberg S., Lilleberg J., Nieminen M.S., and Lehtonen L. Hemodynamic and neurohumoral effects of levosimendan, a new calcium sensitizer, at rest and during exercise in healthy men. Am J Cardiol 75 15 (1995) 1061-1066
94. Szilagyi S., Pollesello P., Levijoki J., Kaheinen P., Haikala H., Edes I., et al. The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. Eur J Pharmacol 486 1 (2004) 67-74
95. Tentolouris C., Tousoulis D., Antoniades C., Bosinakou E., Kotsopoulou M., Trikas A., et al. Endothelial function and proinflammatory cytokines in patients with ischemic heart disease and dilated cardiomyopathy. Intl J Cardiol 94 2-3 (2004) 301
96. Thackray S., Coletta A., Jones P., Dunn A., Clark A.L., and Cleland J.G. Clinical trials update: highlights of the scientific sessions of heart failure 2001, a meeting of the Working Group on Heart Failure of the European Society of Cardiology. CONTAK-CD, CHRISTMAS, OPTIME-CHF. Eur J Heart Fail 3 4 (2001) 491-494
97. Todaka K., Wang J., Yi G.H., Stennett R., Knecht M., Packer M., et al. Effects of levosimendan on myocardial contractility and oxygen consumption. J Pharmacol Exp Ther 279 1 (1996) 120-127
98. Toivonen L., Viitasalo M., Sundberg S., Akkila J., and Lehtonen L. Electrophysiologic effects of a calcium sensitizer inotrope levosimendan administered intravenously in patients with normal cardiac function. J Cardiovasc Pharmacol 35 4 (2000) 664-669
99. Toller W.G., and Stranz C. Levosimendan, a new inotropic and vasodilator agent. Anesthesiology 104 3 (2006) 556-569
100. Trikas A., Antoniades C., Latsios G., Vasiliadou K., Karamitros I., Tousoulis D., et al. Long-term effects of levosimendan infusion on inflammatory processes and sFas in patients with severe heart failure. Eur J Heart Fail (2006)
101. Ukkonen H., Saraste M., Akkila J., Knuuti J., Karanko M., Iida H., et al. Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther 68 5 (2000) 522-531
102. 2+ current in rat ventricular myocytes. Br J Pharmacol 127 1 (1999) 65-74
103. Wilde A.A., and Janse M.J. Electrophysiological effects of ATP sensitive potassium channel modulation: implications for arrhythmogenesis. Cardiovasc Res 28 1 (1994) 16-24
104. + channel in rat arterial myocytes. Eur J Pharmacol 333 2-3 (1997) 249-259
105. + channel in rat ventricular cells. J Pharmacol Exp Ther 283 1 (1997) 375-383
106. Yokoshiki H., and Sperelakis N. Vasodilating mechanisms of levosimendan. Cardiovasc Drugs Ther 17 2 (2003) 111-113
107. Yokoyama T., Vaca L., Rossen R.D., Durante W., Hazarika P., and Mann D.L. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest 92 5 (1993) 2303-2312
108. Zaccolo M. Phosphodiesterases and compartmentalized cAMP signalling in the heart. Eur J Cell Biol 85 7 (2006) 693
109. Zairis M.N., Apostolatos C., Anastasiadis P., Mytas D., Katsaris C., Kouris N., et al. 835-6. The effect of a calcium sensitizer or an inotrope or none in chronic low output decompensated heart failure: results from the calcium sensitizer or inotrope or none in low output heart failure study (CASINO). J Am Col Cardiol 43 5, Supplement 1 (2004) A206